FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
Recommended
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
Based on data from the open-label, multicenter, single-arm NP30179 trial, the FDA has approved glofitamab-gxbm for patients with relapsed/refractory DLBCL, not otherwise specified, or LBCL arising from FL after ≥2 lines of systemic therapy.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->